Article info

Download PDFPDF

Extended report
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
  1. Correspondence to Ronald F. van Vollenhoven, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, 17176 Stockholm, Sweden; ronald.van.vollenhoven{at}ki.se
View Full Text

Citation

van Vollenhoven RF, Petri MA, Cervera R, et al
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

Publication history

  • Received October 19, 2011
  • Accepted December 30, 2011
  • First published February 15, 2012.
Online issue publication 
July 14, 2012

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.